Recently, the combination of AZA plus venetoclax, a BCL2 inhibitor, has been shown to be superior to AZA alone in several large clinical trials, inducing longer overall survival and higher incidence of remission in elderly AML and high-risk MDS patients (DiNardo et al., 2018; Ball et al., 2020; DiNardo et al., 2020; Pollyea et al., 2021). The gene discussed is BCL2; the disease is myelodysplastic syndrome.